A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile

Virchows Archiv

Volumn 445, Issue 3, 2004, Pages 236-247

  Monti, Paolo ^a   Marchesi, Federica ^b   Reni, Michele ^a   Mercalli, Alessia ^a   Sordi, Valeria ^a   Zerbi, Alessandro ^a   Balzano, Giampaolo ^a   Di Carlo, Valerio ^a   Allavena, Paola ^b   Piemonti, Lorenzo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Apoptosis; Cell lines; Chemo sensitivity; Immunoescape; Pancreatic cancer

Indexed keywords

CCL22 CHEMOKINE; CHEMOKINE; CYTOKINE; FAS ANTIGEN; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN; OXALIPLATIN; RALTITREXED; RANTES; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANEUPLOIDY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL DIVISION; CELL LINE, TUMOR; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; PANCREATIC NEOPLASMS; PHENOTYPE;

EID: 4644371375     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-004-1053-x     Document Type: Article

References (68)

1. Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer statistics. CA Cancer J Clin 47:5-27
2. Wanebo HJ, Vezeridis MP (1996) Pancreatic carcinoma in perspective. A continuing challenge. Cancer 78[Suppl]:580-591
3. Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzese JL (2000) A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 95:17-31
4. Wolff RA, Chiao P, Lenzi R, Pisters PW, Lee JE, Janjan NA et al (2000) Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs 18:43-56
5. Abbruzzese JL (2002) New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 95[Suppl]:941-945
6. Bardeesy N, DePinho RA (2002) Pancreatic cancer biology and genetics. Nat Rev Cancer 2:897-909
7. Ruiz-Cabello F, Garrido F (1998) HLA and cancer: from research to clinical impact. Immunol Today 19:539-542
8. Pardoll D (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807-839
9. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998
10. Chouaib S, Thiery J, Gati A, Guerra N, El Behi M, Dorothee G et al (2002) Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death. Tissue Antigens 60:273-281
11. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G (2003) A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 442:444-452
12. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR et al (2001) Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 439:798-802
13. Vila MR, Lloreta J, Schussler MH, Berrozpe G, Welt S, Real FX (1995) New pancreas cancers cell lines that represent distinct stages of ductal differentiation. Lab Invest 72:395-404
14. Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Buchler MW (2001) Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen 21:27-44
15. Shi X, Friess H, Kleeff J, Ozawa F, Buchler MW (2001) Pancreatic cancer: factors regulating tumor development, maintenance and metastasis. Pancreatology 1:517-524
16. Kloppel G, Lingenthal G, von Bulow M, Kern HF (1985) Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: studies in xenografted tumours and clinico- histopathological correlation in a series of 75 cases. Histopathology 9:841-856
17. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G (1975) Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15:741-747
18. Yunis AA, Arimura GK, Russin DJ (1977) Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 19:218-235
19. Elsasser HP, Lehr U, Agricola B, Kern HF (1993) Structural analysis of a new highly metastatic cell line PaTu 8902 from a primary human pancreatic adenocarcinoma. Virchows Arch 64:201-207
20. Drucker BJ, Marincola FM, Siao DY, Donlon TA, Bangs CD, Holder WD Jr (1988) A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice. In Vitro Cell Dev Biol 24:1179-1187
21. Fogh J, Wright WC, Loveless JD (1977) Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58:209-214
22. Kyriazis AP, Kyriazis AA, Scarpelli DG, Fogh J, Rao MS, Lepera R (1982) Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. Am J Pathol 106:250-260
23. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M (1994) Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 58:185-191
24. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G et al (1993) p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 8:289-298
25. Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W (1996) Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 110:1215-1224
26. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL et al (1996) DPC4 gene in various tumor types. Cancer Res 56:2527-2530
27. McIntosh JC, Schoumacher RA, Tiller RE (1988) Pancreatic adenocarcinoma in a patient with cystic fibrosis. Am J Med 85:592
28. Schoumacher RA, Ram J, Iannuzzi MC, Bradbury NA, Wallace RW, Hon CT et al (1990) A cystic fibrosis pancreatic adenocarcinoma cell line. Proc Natl Acad Sci U S A 87:4012-4016
29. Owens RB, Smith HS, Nelson-Rees WA, Springer EL (1976) Epithelial cell cultures from normal and cancerous human tissues. J Natl Cancer Inst 56:843-849
30. Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A (2001) Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep 8:89-92
31. Fink SP, Mikkola D, Willson JK, Markowitz S (2003) TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene 22:1317-1323
32. Yamaguchi N, Uozumi G, Ikeuchi H, Morioka H, Machino M, Kawai K (1983) Establishment and characterization of a carcinoembryonic antigen producing cell line derived from human pancreatic exocrine cancer. Gastroenterol Jpn 18:585-592
33. Okabe T, Yamaguchi N, Ohsawa N (1983) Establishment and characterization of a carcinoembryonic antigen (CEA)-producing cell line from a human carcinoma of the exocrine pancreas. Cancer 51:662-668
34. Hirai H, Okabe T, Anraku Y, Fujisawa M, Urabe A, Takaku F (1985) Activation of the c-K-ras oncogene in a human pancreas carcinoma. Biochem Biophys Res Commun 127:168-174
35. Tan MH, Shimano T, Chu TM (1981) Differential localization of human pancreas cancer-associated antigen and carcinoembryonic antigen in homologous pancreatic tumoral xenograft. J Natl Cancer Inst 67:563-569
36. Chen WH, Horoszewicz JS, Leong SS, Shimano T, Penetrante R, Sanders WH et al (1982) Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro 18:24-34
37. Metzgar RS, Gaillard MT, Levine SJ, Tuck FL, Bossen EH, Borowitz MJ (1982) Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. Cancer Res 42:601-608
38. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G et al (1991) Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 64:1076-1082
39. Peri G, Milanese C, Matteucci C, Ruco L, Zhou D, Sozzani S et al (1994) A new monoclonal antibody (5D3-F7) which recognizes human monocyte-chemotactic protein-1 but not related chemokines. Development of a sandwich ELISA and in situ detection of producing cells. J Immunol Methods 174:249-257
40. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E et al (2000) Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 164:4443-4451
41. Miller DW, Fontain M, Kolar C, Lawson T (1996) The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett 107:301-306
42. Torres MJ, Ruiz-Cabello F, Skoudy A, Berrozpe G, Jimenez P, Serrano A et al (1996) Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 47:372-381
43. Scupoli MT, Sartoris S, Tosi G, Ennas MG, Nicolis M, Cestari T et al (1996) Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens 48:301-311
44. Pernick NL, Sarkar FH, Tabaczka P, Kotcher G, Frank J, Adsay NV (2002) Fas and Fas ligand expression in pancreatic adenocarcinoma. Pancreas 25:36-41
45. Kommann M, Ishiwata T, Kleeff J, Beger HG, Korc M (2000) Fas and Fas-ligand expression in human pancreatic cancer. Ann Surg 231:368-379
46. Ungefroren H, Voss M, Bernstorff WV, Schmid A, Kremer B, Kalthoff H (1999) Immunological escape mechanisms in pancreatic carcinoma. Ann N Y Acad Sci 880:243-251
47. Wright P, Braun R, Babiuk L, Littel-van den Hurk SD, Moyana T, Zheng C et al (1999) Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm 14:49-57
48. Stoelcker B, Ruhland B, Hehlgans T, Bluethmann H, Luther T, Mannel DN (2000) Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol 156:1171-1176
49. Thomas WJ, Thomas DL, Knezetic JA, Adrian TE (2002) The role of oxygen-derived free radicals and nitric oxide in cytokine-induced antiproliferation of pancreatic cancer cells. Pancreas 24:161-168
50. Gansauge S, Nussler AK, Beger HG, Gansauge F (1998) Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a G1-arrest and an increase of the cyclin-dependent kinase inhibitor p21WAF1/CIP1. Cell Growth Differ 9:611-617
51. Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F et al (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63:7451-7461
52. Alexandroff AB, Jackson AM, Paterson T, Haley JL, Ross JA, Longo DL et al (2000) Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 37:515-526
53. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW (1998) CD40 and epithelial cells: across the great divide. Immunol Today 19:502-506
54. Paulie S, Ehlin-Henriksson B, Mellstedt H, Koho H, Ben-Aissa H, Perlmann P (1985) A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother 20:23-28
55. Romagnani S (2002) Cytokines and chemoattractants in allergic inflammation. Mol Immunol 38:881-885
56. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D et al (1999) Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155:537-547
57. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M et al (2002) The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62:1093-1102
58. Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F et al (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63:7451-7461
59. Takaya H, Andoh A, Shimada M, Hata K, Fujiyama Y, Bamba T (2000) The expression of chemokine genes correlates with nuclear factor-kappaB activation in human pancreatic cancer cell lines. Pancreas 21:32-40
60. Shimada M, Andoh A, Araki Y, Fujiyama Y, Bamba T (2001) Ligation of the Fas antigen stimulates chemokine secretion in pancreatic cancer cell line PANC-1. J Gastroenterol Hepatol 16:1060-1067
61. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K (1999) Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 5:3711-3721
62. Miyamoto M, Shimizu Y, Okada K, Kashii Y, Higuchi K, Watanabe A (1998) Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells. Cancer Immunol Immunother 47:47-57
63. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S et al (2000) Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 6:3530-3535
64. Baker CH, Solorzano CC, Fidler IJ (2001) Angiogenesis and cancer metastasis: antiangiogenic therapy of human pancreatic adenocarcinoma. Int J Clin Oncol 6:59-65
65. Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H (2003) Invasion and metastasis in pancreatic cancer. Mol Cancer 2:14
66. von Bemstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C et al (2001) Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7:925-932
67. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756-2761
68. Arlt A, Vomdamm J, Muerkoster S, Yu H, Schmidt WE, Folsch UR et al (2002) Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 62:910-916